First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Julius StraussJean-Laurent DevilleMario SznolAlain RavaudMarco MaruzzoRussell K PachynskiTheodore S GourdinMichele MaioLuc DirixJeffrey SchlomRenee N DonahueYo-Ting TsaiXiaoZhe WangYulia VugmeysterFrank BeierJoerg SeebeckAndreas SchroederSarah ChennoufiJames L GulleyPublished in: Journal for immunotherapy of cancer (2023)
M9241 plus avelumab was well tolerated at all DLs, including the dose-expansion part, with no new safety signals. However, the dose-expansion part did not meet the predefined efficacy criterion to proceed to stage 2.